Skip to content

Effect of Pistacia atlantica oleoresin in treatment of cutaneous leishmaniasis

Evaluation of the efficacy of the topical use of Pistacia atlantica oleoresin in the treatment of acute cutaneous leishmaniasis wound: a pilot randomized, double-blind, placebo-controlled clinical trial

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20090804002288N17
Enrollment
20
Registered
2024-10-14
Start date
2024-11-21
Completion date
Unknown
Last updated
2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

?Acute cutaneous leishmaniasis. Cutaneous leishmaniasis

Interventions

Intervention 1: Intervention group: Applies the 50% weight/weight Pistacia atlantica oleoresin cream to the lesion every 12 hours for 8 weeks. Intervention 2: Control group: Applies the cream lacking

Sponsors

Iranian academic center for education culture and research
Lead Sponsor
Esfahan University of Medical Sciences
Collaborator

Eligibility

Sex/Gender
All
Age
5 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients whose cutaneous leishmaniasis diagnosis has been confirmed by test Patients whose lesions size is less than 3 centimeters Patients who have 2 symmetrical lesions Patients whose lesions are not on cartilage or joint Patients whose lesions are not on the face Patients whose lesions are not in sight Patients who do not need to receive Glucantime (antimoniate)

Exclusion criteria

Exclusion criteria: Women who are in the childbearing age Women who breastfeed Patients who have sporotrichoid or satellite lesions Patients who have used immunosuppresive drugs during the past 6 months Patients who have received topical or systemic antileishmanial drugs during the past 1 month

Design outcomes

Primary

MeasureTime frame
Lesion area. Timepoint: Measurement of the lesion area before intervention and 2, 4, 8 and 12 weeks after intervention. Method of measurement: Graph paper.;Percentage of patients who have amastigotes in the lesion. Timepoint: Evaluation of the presence of amastigotes in the lesion before intervention and 4, 8 and 12 weeks after intervention. Method of measurement: Direct smear method.

Secondary

MeasureTime frame
Complete blood count. Timepoint: Before intervention and 8 weeks after intervention. Method of measurement: Auto-analyzer.;Serum glutamic pyruvic transaminase. Timepoint: Before intervention and 8 weeks after intervention. Method of measurement: Autoanalyzer.;Serum glutamic oxaloacetic transaminase. Timepoint: Before intervention and 8 weeks after intervention. Method of measurement: Autoanalyzer.;Blood creatinine. Timepoint: Before intervention and 8 weeks after intervention. Method of measurement: Autoanalyzer.;Blood urea nitrogen. Timepoint: Before intervention and 8 weeks after intervention. Method of measurement: Autoanalyzer.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Saeed Kianbakht

Iranian academic center for education culture and research

skianbakht@yahoo.com+98 26 3476 4010

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026